×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:AXGN

AxoGen (AXGN) Stock Forecast, Price & News

$9.72
+0.14 (+1.46%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$9.43
$9.82
50-Day Range
$6.99
$10.00
52-Week Range
$6.87
$22.82
Volume
207,181 shs
Average Volume
346,054 shs
Market Capitalization
$408.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.75
30 days | 90 days | 365 days | Advanced Chart
Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AxoGen logo

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXGN
Employees
428
Year Founded
N/A

Sales & Book Value

Annual Sales
$127.36 million
Book Value
$2.47 per share

Profitability

Net Income
$-26.99 million
Pretax Margin
-24.98%

Debt

Price-To-Earnings

Miscellaneous

Free Float
38,828,000
Market Cap
$408.06 million
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/27/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

461st out of 1,424 stocks

Electromedical Equipment Industry

8th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













AxoGen (NASDAQ:AXGN) Frequently Asked Questions

Is AxoGen a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AxoGen stock.
View analyst ratings for AxoGen
or view top-rated stocks.

When is AxoGen's next earnings date?

AxoGen is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for AxoGen
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings data on Wednesday, May, 4th. The medical equipment provider reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.03. The medical equipment provider earned $31.01 million during the quarter, compared to analyst estimates of $30.40 million. AxoGen had a negative net margin of 24.98% and a negative trailing twelve-month return on equity of 26.64%. During the same quarter in the previous year, the business earned ($0.15) earnings per share.
View AxoGen's earnings history
.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$142.00 million, compared to the consensus revenue estimate of $137.94 million.

What price target have analysts set for AXGN?

4 brokerages have issued 1-year price targets for AxoGen's shares. Their forecasts range from $15.00 to $27.00. On average, they expect AxoGen's share price to reach $19.25 in the next year. This suggests a possible upside of 98.0% from the stock's current price.
View analysts' price targets for AxoGen
or view top-rated stocks among Wall Street analysts.

Who are AxoGen's key executives?
AxoGen's management team includes the following people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 60, Pay $1.16M) (LinkedIn Profile)
  • Mr. Peter J. Mariani, Exec. VP & CFO (Age 58, Pay $696.4k)
  • Ms. Maria D. Martinez, Chief HR Officer (Age 54, Pay $498.62k) (LinkedIn Profile)
  • Mr. Angelo G. Scopelianos Ph.D., Chief R&D Officer (Age 67, Pay $613.99k)
  • Mr. Eric A. Sandberg, Chief Commercial Officer (Age 57, Pay $529k)
  • Mr. Michael Donovan, VP of Operations (Age 57)
  • Ed Joyce, Director of Investor Relations
  • Mr. Bradley L. Ottinger J.D., Gen. Counsel & Chief Compliance Officer (Age 52)
  • Mr. Gregory Davault, VP of Marketing (Age 54)
  • Ms. Isabelle Billet, Chief Strategy & Bus. Devel. Officer (Age 60)
What is Karen Zaderej's approval rating as AxoGen's CEO?

3 employees have rated AxoGen CEO Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among AxoGen's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.18%), First Light Asset Management LLC (5.77%), Vanguard Group Inc. (4.58%), William Blair Investment Management LLC (3.88%), State Street Corp (2.57%) and Assenagon Asset Management S.A. (1.64%). Company insiders that own AxoGen stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends for AxoGen
.

Which institutional investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Exchange Traded Concepts LLC, Skandinaviska Enskilda Banken AB publ , Dimensional Fund Advisors LP, UBS Group AG, Goldman Sachs Group Inc., Northern Trust Corp, and Engineers Gate Manager LP. Company insiders that have sold AxoGen company stock in the last year include Karen L Zaderej, Maria D Martinez, and Michael Patrick Donovan.
View insider buying and selling activity for AxoGen
or view top insider-selling stocks.

Which institutional investors are buying AxoGen stock?

AXGN stock was purchased by a variety of institutional investors in the last quarter, including SCW Capital Management LP, Assenagon Asset Management S.A., CI Investments Inc., Friess Associates LLC, First Light Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., and William Blair Investment Management LLC.
View insider buying and selling activity for AxoGen
or or view top insider-buying stocks.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $9.72.

How much money does AxoGen make?

AxoGen has a market capitalization of $408.06 million and generates $127.36 million in revenue each year. The medical equipment provider earns $-26.99 million in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does AxoGen have?

AxoGen employs 428 workers across the globe.

What is AxoGen's official website?

The official website for AxoGen is www.axogeninc.com.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at (386) 462-6800, via email at [email protected], or via fax at 386-462-6801.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.